pharmacological doses of folic acid lowers the plasma Introduction homocysteine concentration in these patients. The purpose of the present study was to expand the knowledge Hyperhomocysteinaemia has been recognized as an about such treatment by testing the effects of stepwise independent atherothrombotic risk factor [1, 2] potenincreases in the dose of folic acid on the concentrations tially explaining as much as 10% of the coronary artery of plasma and red blood cell folate as well as the disease in the general population [3] . The mechanisms total plasma concentrations of homocysteine (tHcy), behind this have not been fully elucidated but seem cysteine (tCys), and glutathione (tGSH ) in patients on to involve endothelial dysfunction and increased chronic hemodialysis.
thrombogenicity [4, 5] . The plasma concentration of Methods. Fourteen stable haemodialysis patients comtotal homocysteine (tHcy) can be lowered by treatment pleted the study which consisted of four consecutive with water-soluble vitamins (folic acid, vitamin B 12 periods, each of 6 weeks duration: (i) no treatment and pyridoxine (vitamin B 6 )), whose precursors act as with folic acid (control period); (ii) 5 mg of folic acid substrates or enzyme cofactors in the homocysteine three times per week (15 mg/week); (iii) 5 mg of folic removal processes [6 ] . In the general population, only acid daily (35 mg/week); (iv) 10 mg of folic acid daily treatment with folic acid has consistently decreased (70 mg/week).
fasting tHcy even in replete subjects [7] . Thus, folic Results. Neither plasma or red cell folate nor plasma acid has become the agent of choice for tHcy-lowering aminothiol concentrations changed significantly during treatment, although as yet there is no evidence the control period. The mean red cell folate concentrathat therapy influences cardiovascular morbidity or tion doubled during the administration of folic acid at mortality [8] . the dose of 15 mg/week but at higher doses the further For unknown reasons, renal insufficiency is associrise was only marginal. The mean folate concentration ated with hyperhomocysteinaemia [9] . In haemoin plasma increased steeply especially at the higher dialysis patients, mean tHcy is roughly threefold that doses of folic acid. During treatment with 15 mg/week of the general population. The development of tHcyof folic acid, tHcy fell by a mean of 36%, tGSH lowering strategies for these patients is of particular increased by a mean of 34%, but tCys was unaffected.
interest due to their greatly increased mortality in Increases in the dose of folic acid did not augment atherosclerotic complications [10] . In addition, in this these responses. patient category folic acid has proved effective, Conclusions. The maximal effect on tHcy seemed to lowering tHcy in dialysis patients by 30-50% [11] [12] [13] [14] [15] . be obtained already at the lowest given dose of folic However, the optimal dose has not been established. acid (15 mg/week). At that dose, the red blood cells
The largely unknown pattern of folate distribution approached folate saturation, which may reflect the associated with different doses of folic acid may be situation in other cells that participate in homocysteine relevant in this context. metabolism and explain why further increases in the The aminothiol cysteine is derived from homodose of folic acid are not effective from a tHcy-lowering cysteine catabolism and, in turn, the synthesis of point of view.
glutathione depends on the availability of cysteine. In dialysis patients, the total plasma concentration of The samples were taken after a light breakfast immediately to the C677T mutation in the methylenetetrahydrofol-before a midweek haemodialysis session. The samples intenate reductase (MTHFR) gene. The main purpose of ded for analysis of aminothiols were placed directly on ice, the study was to document the effects of stepwise centrifuged within an hour, and the plasma stored at −20°C increases in the dose of folic acid on the folate concen-for analysis in the same series. trations in plasma and red blood cells as well the plasma total concentrations of the aminothiols homo-Laboratory investigations cysteine, cysteine, and glutathione. 
Subjects and methods
Plasma was treated with dithiothreitol in order to cleave the disulphide bonds. Thereafter, the concentrations of tHcy,
Patients
tCys and tGSH were measured by high-performance liquid chromatography [19] . The intra-assay variation of the Twenty haemodialysis patients were recruited at the dialysis method for homocysteine analysis was 1.5% and the interasdepartment of the National University Hospital in Reykjavik. say variation was 2.5%. Three patients died of cardiovascular causes during the The C677T polymorphism was determined as previously control or low-dose study periods (see below) and three described using polymerase chain reaction and digestion with patients were excluded due to lack of co-operation. Thus, 14 HinfI restriction endonuclease [20] . patients completed the study. The patients were treated with polysulphone filters (F6, F7, F8) for 4-5 h three times per
Statistical analyses
week. Age, sex, time on dialysis, Kt/V, PCR, and the serum concentrations of albumin as well as cobalamins are shown Data are presented as mean±standard deviations except in Table 1 . At the start of the study, two patients had red data regarding the C677T/MTHFR polymorphism that are cell folate concentrations below the reference range, all the presented as medians (ranges). Friedman's test was applied patients had serum vitamin B 12
concentrations within the to test the variance between the study periods and, in the reference range, and they had received daily supplementation case of a significant difference, the data were directly comwith a multivitamin preparation for at least 3 months. This pared by the Wilcoxon test for paired data. Correlation supplementation, containing 15 mg of pyridoxine but no folic analyses were performed with Spearman's rank correlation acid or vitamin B 12 was continued throughout the study. test. A P value <0.05 was considered to reflect statistical significance.
Procedure
The study consisted of four consecutive periods, each of 6 Results weeks duration:
Weeks 1-6: no treatment with folic acid was given (control With increasing doses of folic acid the folate concentraperiod ).
tions rose markedly, indicating good patient compliWeeks 7-12: folic acid was given at the dose of 5 mg three ance ( Figure 1 ). During treatment with the lowest dose times per week directly after the haemodialysis sessions of folic acid, a steep rise in the mean red blood cell (15 mg/week).
folate concentration was observed, followed by much Weeks 13-18: folic acid was given at the dose of 5 mg daily smaller further increases at the higher doses. In con-(35 mg/week). trast, the mean plasma folate concentration rose steeply Weeks 19-24: folic acid was given at the dose of 10 mg daily at the higher doses of folic acid.
(70 mg/week).
The effects of treatment with folic acid on plasma Blood samples were collected five times during the study, tHcy, tCys, and tGSH are shown in Figure 2 and i.e. at study start and at the end of each period, for analysis Table 2 . According to Friedman's test, the variance between the study periods was significantly different regarding tHcy (P=0.0001) and tGSH (P=0.0001). <16.0 mmol/l ) but after treatment two patients were. Plasma tGSH increased significantly by 34% during treatment but in this case also no additional changes Data, except for sex, are given as means±standard variations. were observed at higher doses of folic acid. Plasma tCys was not affected by treatment.
The correlations between plasma tHcy and folate concentrations in plasma and red blood cells did not reach statistical significance at any time point. Before treatment the coefficient of correlation between plasma tHcy and red blood cell folate was −0.30 but after the different treatment protocols it ranged between −0.02 and 0.02. In addition, the treatment-induced changes in plasma tHcy did not correlate with post-treatment folate concentrations or changes in folate concentrations. The same applied to the other aminothiols except that before treatment tGSH correlated inversely with red blood cell folate concentrations (r=−0.70,
P<0.05).
Plasma tHcy before and after treatment correlated directly (r=0.65, P<0.05). There was a significant inverse correlation between tHcy before treatment and the relative treatment-induced changes in tHcy (r= −0.58, P<0.05). Thus, higher pre-treatment tHcy Fig. 2 . The individual effects of treatment with folic acid on the concentrations were associated with greater treatment-plasma concentration of tHcy in 14 haemodialysis patients (seven in induced reductions. Before treatment, plasma tHcy each graph). During weeks 1-6, no treatment was given; during tended to correlate directly with plasma tCys (r=0.52, weeks 7-12, 5 mg of folic acid were given three times a week directly after haemodialysis sessions; during weeks 13-18, 5 mg of folic acid
P=0.06) and plasma tGSH (r=0.53, P=0.06).
were given daily, and during weeks 19-24, 10 mg of folic acid were After treatment, the correlation between tHcy and given daily. tCys grew stronger (r=0.82, P<0.01) whereas the tendency toward correlation between tHcy and tGSH Discussion disappeared.
Two patients were homozygous with respect to the C677T mutation in the MTHFR gene, four patients In haemodialysis patients, plasma tHcy declined by 36% during treatment with folic acid at the dose of were heterozygous, and eight patients manifested the wild-type alleles. The respective median tHcy concen-15 mg/week. This treatment also induced an increase in plasma tGSH of 34% but did not affect plasma trations (mmol/l ) of these groups before treatment were 40. Table 2 . Plasma concentrations of tHcy, tCys, and tGSH (mmol/l ) other cells than red blood cells, a notion supported by before treatment and after treatment with folic acid at the doses of the steep increases in plasma folate concentrations at 15 mg/week, 35 mg/week, and 70 mg/week the higher doses. Moreover, it has been shown in rats that increased administration of folic acid results in Even during treatment with 16 mg of folic acid, only remethylation pathway is catalysed by the enzyme methionine synthase, which requires vitamin B 12 as a a minority of haemodialysis patients were reported to be normohomocysteinaemic [12] . Accordingly, none cofactor and methyltetrahydrofolate as a substrate. This constitutes the theoretical base for using the of our patients was normohomocysteinaemic before treatment but after treatment, two patients were. One B-vitamins for tHcy-lowering purposes. In the general population, the administration of folic acid lowers patient did not respond at all. This patient was heterozygotic for the C677T mutation and, as judged by his tHcy in most individuals whereas treatment with vitamin B 12 or pyridoxine is of less clinical significance folate concentrations, he was compliant with the treatment. Thus, in most cases of haemodialysis patients, [6, 7] . The same pattern of vitamin response has been found in patients with renal insufficiency, who generally treatment with folic acid substantially lowers tHcy but not to normohomocysteinaemic levels. This probably manifest hyperhomocysteinaemia of unknown mechanism; several studies found no independent reflects a unique influence exerted by the uraemic environment on homocysteine metabolism. However, tHcy-lowering effect of treatment with vitamin B 12 or pyridoxine [11, 13, 21] while treatment with folic acid those who are in the greatest need for treatment, i.e. those who manifest the highest tHcy concentrations, at different doses lowered tHcy by 30-50% [11] [12] [13] [14] [15] . Treatment with other agents of theoretical interest such respond most markedly. This is illustrated in Figure 2 by the treatment-induced narrowing of the tHcy range. as betaine [22] or serine [23] did not significantly lower tHcy in dialysis patients. In spite of folic acid obviously Possibly, treatment with methyltetrafolate, the active form of folate, will prove to be superior. A promising being the cornerstone of tHcy-lowering treatment in haemodialysis patients, few studies have compared the treatment trial has been performed with methyltetrahydrofolate, but in that study no comparison was made tHcy-lowering effect or documented the folate distribution in response to different doses of folic acid. There with folic acid [25] .
In those haemodialysis patients who lie beneath the is as yet no consensus about the optimal dosage of folic acid in this setting, while the literature gives the median in folate concentration, homozygosity for the thermolabile variant of the enzyme MTHFR (C677T general impression that very high doses are needed for maximal tHcy-lowering effect. mutation) has been shown to predispose to increased tHcy [26 ] . In the present study there was no difference The maximal tHcy-lowering response to folic acid seemed to be obtained already at the dose of in the relative response to folic acid between the two patients who were homozygous for the above-15 mg/week administered directly after the haemodialysis sessions ( Figure 2 and Table 2 ). The individual mentioned mutation and those eight patients who did not carry this mutation at all. However, the groups curves in Figure 2 in no case gave the impression of a substantial or consequent increase in response to the were too small for statistical analysis.
Catabolism of homocysteine takes place in the transsuccessively increased dose of folic acid. It is of interest to note that during treatment with 15 mg/week of folic sulphuration pathway. In the first steps, catalysed by cystathionine-b-synthase, cysteine is formed. Cysteine, acid, the mean red blood cell folate concentration doubled, whereas subsequent manifold increases in the in turn, is necessary for glutathione synthesis. In the present study, treatment with folic acid lowered tHcy, dose of folic acid only resulted in marginal further increases in the red blood cell folate concentration. left tCys unaffected and raised tGSH. These findings seem to be paradoxical. The folate-induced increase in Thus, the red blood cells seemed to approach folate saturation already at the lowest given dose of folic the remethylation would be expected to reduce the load on the trans-sulphuration pathway, which should acid. These results probably reflect the situation in high-dose pyridoxine and folic acid supplementation on serum result in a decrease in tCys and tGSH unless intracellu- Determination of homocysteine and other thiols in human plasma by high-performance liquid chromatography and a thiol-
